Claudin18.2 Targeted CAR-T Cells therapy (Frontiergate Biopharm)

Claudin18.2靶向CAR-T细胞疗法（珈钰生物）

Report date: 2026/04/17 20:02:02

Base Information

Drug NameClaudin18.2 Targeted CAR-T Cells therapy (Frontiergate Biopharm)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionT lymphocyte replacementsAnti-CLDN18

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesFrontiergate Biopharm (Hainan) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesFrontiergate Biopharm (Hainan) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A